Search Results - combination+therapy

8 Results Sort By:
Targeted Epigenetic Editing as Novel Therapy for Malignant Glioma (UCLA Case No. 2023-047)
UCLA Researchers in the Department of Neurology/Neuro-Oncology and the David Geffen School of Medicine have developed methods for the Cas9-CRISPR mediated epigenetic targeting of malignant glioma, and which results in enhanced chemosensitivity to standard chemotherapeutic agents. BACKGROUND: Malignant gliomas are aggressive brain tumors originating...
Published: 1/17/2024   |   Inventor(s): Serendipity Zapanta Rinonos, Albert Lai
Keywords(s): Brain, Cancer, Cancer stem cells, Chemotherapy, Combination therapy, CRISPR, CRISPR-Cas9, Epigenetics, GBM, Glioma
Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology
Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery
Abstract: The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of: A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine...
Published: 4/8/2024   |   Inventor(s): Anu Puri, Robert Blumenthal, Amit Joshi, Darayash Tata, Mathias Viard
Keywords(s): Combination Therapy, Delivery Agent, Infections (bacteria and viruses), Lipid nanoparticle, liposome, On-demand Drug Release, photoactivation, therapeutic delivery
Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Dermatology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Opthamology, TherapeuticArea > Eye / Ear / Nose / Throat, Collaboration Sought > Licensing, TherapeuticArea > Cardiology
Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation
Abstract: Common methods of cancer therapy largely rely on either direct killing of cancer cells or activation of the host immune response to do so, but not both. A recently developed treatment of tumors uses an antibody/photo-absorber, Ab-IR700, with near infrared photoimmunotherapy (NIR-PIT), to selectively kill IR700-bound and NIR-light-exposed cancer...
Published: 9/19/2024   |   Inventor(s): Hisataka Kobayashi, Peter Choyke
Keywords(s): antibody-IR700, Combination Therapy, Immunomodulators, Immunotherapy, Kobayashi, Metastasis, Near-Infrared Photo Immunotherapy, NIR-PIT, Photochemical, Tumor Inhibition
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Combination Cancer Therapy with HDAC Inhibitors
Abstract: The clinical promise of cancer immunotherapy relies on the premise that the immune system can recognize and eliminate tumor cells identified as non-self. The success of cancer immunotherapy is limited by tumor immune evasion, preventing long-lasting tumor control. Recent evidence suggests that certain anticancer therapies can alter the biology...
Published: 4/8/2024   |   Inventor(s): James Hodge, Sofia Gameiro
Keywords(s): Combination Therapy, CTL, HDAC inhibition, Immunotherapy
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.
Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....
Published: 5/22/2024   |   Inventor(s): Md Alam, De Yang, Joost Oppenheim
Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination
Abstract: Researchers at the National Cancer Institute (NCI) have developed a method of stimulating an immune response in humans at risk for infection by, or already infected with, an Human Immunodeficiency Virus (HIV)-1 retrovirus. This method utilizes deoxyribonucleic acid (DNA) vaccines to stimulate CD8+ T cell immune responses. The DNA vaccine encodes...
Published: 8/5/2024   |   Inventor(s): Genoveffa Franchini, Zdenek Hel, George Pavlakis, James Tartaglia
Keywords(s): Combination Therapy, CTL, cytotoxic T lymphocyte, Deoxyribonucleic Acid, DNA vaccine, Franchini, HIV, Human Immunodeficiency Virus, POX VIRUS
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Vaccines
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...
Published: 7/29/2024   |   Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney
Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Nanococktail for combination therapy, compositions, methods, and uses
INV-20007 Background It is difficult to achieve optimal exposure of all agents in combination therapy with drugs that exhibit different properties. Nanoparticle delivery systems are a well-known means to modify the pharmacokinetics and distribution of drugs. Northeastern researchers have demonstrated that through nanoencapsulation, similar pharmacokinetic...
Published: 9/10/2024   |   Inventor(s): Srinivas Sridhar, Paige Baldwin, Bijay Singh
Keywords(s): Combination therapy, Drug Delivery, Nanomedicine, Therapeutic, Treatment
Category(s): -Nanotechnology, -Materials